<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619435</url>
  </required_header>
  <id_info>
    <org_study_id>STREAM</org_study_id>
    <secondary_id>2015-001105-13</secondary_id>
    <nct_id>NCT02619435</nct_id>
  </id_info>
  <brief_title>Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer</brief_title>
  <acronym>STREAM</acronym>
  <official_title>Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to purpose of this study is to assess if regorafenib is active&#xD;
      enough, in terms of 6-month progression-free rate, to warrant further comparative studies in&#xD;
      patients with RAS-mutant advanced colorectal cancer who have progressed after first-line&#xD;
      oxaliplatin-based chemotherapy plus bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rate of evaluable patients alive and not progressed at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>every 4 weeks up to 1 year</time_frame>
    <description>evaluated according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with complete plus partial response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to one year</time_frame>
    <description>the time from registration to progression or death without progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>as the time from registration to the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regorafenib</intervention_name>
    <description>Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.</description>
    <arm_group_label>regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of colorectal adenocarcinoma&#xD;
&#xD;
          2. Any RAS mutation that prevent treatment with anti-EGFR antibodies&#xD;
&#xD;
          3. Stage IV&#xD;
&#xD;
          4. Measurable disease according to RECIST v. 1.1&#xD;
&#xD;
          5. Disease progression during or following a treatment with fluoropyrimidine, oxaliplatin&#xD;
             and bevacizumab, and a treatment with irinotecan is not considered immediately&#xD;
             mandatory by the Investigator&#xD;
&#xD;
          6. Age ≥ 18 years&#xD;
&#xD;
          7. ECOG Performance Status 0-1&#xD;
&#xD;
          8. Neutrophils &gt; 1500 / mm3, platelets &gt; 100,000 / mm3, and hemoglobin &gt; 9 g/dL without&#xD;
             transfusion or granulocyte-colony stimulating factor (G-CSF) and other hematopoietic&#xD;
             growth factors.&#xD;
&#xD;
          9. Bilirubin level &lt; 1.5 x ULN&#xD;
&#xD;
         10. Glomerular filtration rate &gt; 30 mL/min/1.73 m2 according to the Modified Diet in Renal&#xD;
             Disease abbreviated formula&#xD;
&#xD;
         11. AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN (≤ 5 x ULN if liver metastasis are present)&#xD;
&#xD;
         12. Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN if liver metastasis are present)&#xD;
&#xD;
         13. Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
         14. Amylase and lipase ≤ 1.5 x ULN&#xD;
&#xD;
         15. INR and aPTT ≤ 1.5 x ULN. Subjects who are therapeutically treated with an agent such&#xD;
             as warfarin or heparin will be allowed to participate if no underlying abnormality in&#xD;
             coagulation parameters exists per medical history.&#xD;
&#xD;
         16. Understand, be willing to give consent, and sign the written informed consent form&#xD;
             (ICF) prior to undergoing any study-specific procedure.&#xD;
&#xD;
         17. If female and of childbearing potential, have a negative result on a pregnancy test&#xD;
             performed a maximum of 7 days before initiation of study treatment.&#xD;
&#xD;
         18. If potentially childbearing female, or if male, agree to use adequate contraception&#xD;
             (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method)&#xD;
             from the date on which the ICF is signed until 8 weeks after the last dose of study&#xD;
             drug.&#xD;
&#xD;
         19. Life expectancy of greater than 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with regorafenib or irinotecan&#xD;
&#xD;
          2. Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir,&#xD;
             itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir,&#xD;
             saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine,&#xD;
             phenobarbital, phenytoin, rifampin, St. John's Wort)&#xD;
&#xD;
          3. Have had a major surgical procedure, open biopsy, or significant traumatic injury&#xD;
             within 28 days prior to initiation of study treatment&#xD;
&#xD;
          4. Have congestive heart failure classified as New York Heart Association Class 2 or&#xD;
             higher&#xD;
&#xD;
          5. Have had unstable angina (angina symptoms at rest) or new-onset angina &lt; 3 months&#xD;
             prior to screening.&#xD;
&#xD;
          6. Have had a myocardial infarction &lt; 6 months prior to initiation of study treatment.&#xD;
&#xD;
          7. Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta&#xD;
             blockers or digoxin.&#xD;
&#xD;
          8. Have had arterial or venous thrombotic or embolic events such as cerebrovascular&#xD;
             accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary&#xD;
             embolism within 6 months prior to the initiation of study treatment&#xD;
&#xD;
          9. Symptomatic brain metastases or meningeal tumors&#xD;
&#xD;
         10. Patients with evidence or history of bleeding diathesis&#xD;
&#xD;
         11. Uncontrolled hypertension (systolic blood pressure [SBP] &gt;140 mmHg or diastolic blood&#xD;
             pressure [DBP] &gt; 90 mmHg)&#xD;
&#xD;
         12. Have interstitial lung disease with ongoing signs and symptoms at the time informed&#xD;
             consent is obtained&#xD;
&#xD;
         13. Have persistent proteinuria &gt; 3.5 g/24 hours measured by urine protein creatinine&#xD;
             ratio from a random urine sample (&lt; Grade 3, CTCAE v 4.0).&#xD;
&#xD;
         14. Have unresolved toxicity higher than National Cancer Institute-Common Terminology for&#xD;
             Adverse Events version 4.0 (CTCAE v 4.0) Grade 1 attributed to any prior&#xD;
             therapy/procedure, excluding alopecia and/or oxaliplatin-induced neurotoxicity ≤ Grade&#xD;
             2 and hemoglobin ≥ 9 g/dL as per inclusion criteria&#xD;
&#xD;
         15. Patients who cannot take oral medication, who require intravenous alimentation, have&#xD;
             had prior surgical procedures affecting absorption, or have active peptic ulcer&#xD;
             disease&#xD;
&#xD;
         16. Pregnant or lactating women&#xD;
&#xD;
         17. Any other malignancies within 5 years (except for adequately treated carcinoma in situ&#xD;
             of the cervix or non melanoma skin cancer)&#xD;
&#xD;
         18. Any unstable systemic disease (including active infections, any significant hepatic,&#xD;
             renal or metabolic disease), metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding that contraindicates the use of regorafenib or render the&#xD;
             patient at high risk for treatment complications&#xD;
&#xD;
         19. Sexually active males and females (of childbearing potential) unwilling to practice&#xD;
             contraception during the study.&#xD;
&#xD;
         20. Have any other serious or unstable illness, or medical, psychological, or social&#xD;
             condition, that could jeopardize the safety of the subject and/or his/her compliance&#xD;
             with study procedures, or may interfere with the subject's participation in the study&#xD;
             or evaluation of the study results.&#xD;
&#xD;
         21. Have a known hypersensitivity to any of the study drugs, study drug classes, or&#xD;
             excipients in the formulation of the study drugs.&#xD;
&#xD;
         22. Have a close affiliation with the investigational site (eg, be a close relative of the&#xD;
             investigator) or be a dependent person (eg, be an employee or student working at the&#xD;
             investigational site).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Avallone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Budillon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AO G. Rummo</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Università di Napoli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO S. Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAS-mutant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

